{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017782","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.710973+00:00","generated_at":"2026-06-02T22:13:29.139315+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivos awaits Nasdaq confirmation on equity compliance; warns of delisting risk if capital insufficient","bullets":["Company believes it met $2.5M minimum equity requirement by March 19, 2024, via capital raises in Nov 2023 and Feb 2024.","Nasdaq has not yet confirmed compliance; will monitor ongoing compliance at next periodic report.","Company expects to need additional equity capital to maintain compliance; failure could lead to delisting.","Delisting would materially harm stock price, liquidity, capital raising ability, and reputation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017782","json":"https://secwatch.observer/filing/0001493152-24-017782.json","markdown":"https://secwatch.observer/filing/0001493152-24-017782.md","text":"https://secwatch.observer/filing/0001493152-24-017782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224017782/0001493152-24-017782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224017782/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:13:29.139315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}